🔎 Trials Near Me

Dachaigh › Aillse Prostata › Tennessee

Sgrùdaidhean clionaigeach Aillse Prostata ann an Tennessee

Tha 50 sgrùdaidhean airson Aillse Prostata a’ lorg phàirtichean aig làraichean ann an Tennessee.

Bailtean ann an Tennessee

Teacsa sgrùdaidh oifigeil (Beurla)

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

  • GSK Investigational Site, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 5 Dàmh 2026 · NCT06990880

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

  • Urology Associates, Nashville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 5 Dàmh 2026 · NCT07723248

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • Sarah Cannon Research Institute, Nashville
  • Tennessee Oncology PLLC, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06465069

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Sarah Cannon Research Institute, Nashville
A’ fastadhÌre 1/2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT04585750

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • SCRI Oncology Partners, Nashville
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06172478

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Vanderbilt University/Ingram Cancer Center, Nashville
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT03866382

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

  • Tennessee Oncology, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 28 Sult 2026 · NCT06095089

DESTINY-PANTUMOUR04

  • Research Site, Nashville
A’ fastadhSgrùdadh amharc
Aoisean 18 gu 130 · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07124000

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

  • Sarah Cannon Research Institute, Nashville
  • Urology Associates, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 25 Sult 2026 · NCT06800313

A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer

  • The Conrad Pearson Clinic, Germantown
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 25 Sult 2026 · NCT07832292

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  • The West Clinic, PLLC dba West Cancer Center ( Site 0063), Germantown
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06136650

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  • Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
  • Tennessee Oncology PLLC, Chattanooga
  • Tennessee Oncology, PLLC - Chattanooga Med Park II, Chattanooga
  • agus 20 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 24 Sult 2026 · NCT07028853

A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

  • Tennessee Oncology, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 24 Sult 2026 · NCT07719361

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  • Sarah Cannon Research Institute Oncology Partners, Nashville
  • United States Oncology Regulatory Affairs Corporate Office, Nashville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 22 Sult 2026 · NCT07213674

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  • Tennessee Oncology PLLC, Chattanooga
A’ fastadhÌre 3
Aoisean 18 gu 100 · Fir · Air ùrachadh 22 Sult 2026 · NCT06855277

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  • Research Site, Nashville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 18 Sult 2026 · NCT06952803

Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC

  • Sarah Cannon Research Institute, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 17 Sult 2026 · NCT07813637

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

  • Memphis VA Medical Center, Memphis, TN, Memphis
  • Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 17 Sult 2026 · NCT05011383

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  • Memphis VA Medical Center ( Site 0072), Memphis
  • SCRI Oncology Partners ( Site 0074), Nashville
  • Henry-Joyce Cancer Clinic ( Site 0042), Nashville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 17 Sult 2026 · NCT06925737

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

  • Sarah Cannon Research Institute Oncology Partners, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 15 Sult 2026 · NCT07493512

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

  • Urology Associates of Nashville, Nashville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 11 Sult 2026 · NCT06056830

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

  • Sarah Cannon Research Center, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT06440005

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

  • Sarah Cannon Research Institute, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 4 Sult 2026 · NCT07567846

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

  • Tennessee Oncology Nashville, Nashville
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 3 Sult 2026 · NCT07005154

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

  • SCRI Oncology Partners, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 3 Sult 2026 · NCT07545811

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  • Research Site, Nashville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 26 Lùna 2026 · NCT07611110

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

  • Sarah Cannon Research Institute, Nashville
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 24 Lùna 2026 · NCT07745361

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

  • United States Oncology Regulatory Affairs Corporate Office, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 21 Lùna 2026 · NCT04221542

FOG-001 in Locally Advanced or Metastatic Solid Tumors

  • Sarah Cannon Research Institute, Nashville
  • Vanderbilt Ingram Cancer Center, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Lùna 2026 · NCT05919264

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Henry-Joyce Cancer Clinic, Nashville
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 17 Lùna 2026 · NCT06842498

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

  • Sarah Cannon Research, Nashville
A’ fastadhÌre 1
Aoisean 18 gu 100 · Fir · Air ùrachadh 13 Lùna 2026 · NCT05519449

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

  • Tennessee Oncology PLLC, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Iuch 2026 · NCT07288359

PSMA PET Combined With MRI for the Detection of PCa

  • The Conrad Pearson Clinic, Germantown
  • Urology Associates of Nashville, Nashville
A’ fastadhÌre 3Fàilte do shaor-thoilich fhallain
Aoisean 18 agus nas sine · Fir · Air ùrachadh 23 Iuch 2026 · NCT07052214

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

  • Investigative Site #102, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Iuch 2026 · NCT06545942

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  • Vanderbilt University/Ingram Cancer Center, Nashville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 14 Iuch 2026 · NCT06592924

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

  • Sarah Cannon Research Institute, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 2 Iuch 2026 · NCT07140900

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

  • Memphis VA Medical Center, Memphis
  • Baptist Clinical Research Institute, Memphis
A’ fastadhSgrùdadh amharc
Aoisean 21 agus nas sine · Fir · Air ùrachadh 22 Cèit 2026 · NCT03151629

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

  • Sarah Cannon Research Institute, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 6 Cèit 2026 · NCT06239194

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  • Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
  • Vanderbilt University Medical Center, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Gearr 2026 · NCT06778863

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

  • Urology Associates PC, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 4 Gearr 2026 · NCT04729114

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.